Genome-wide CRISPR screens to identify new therapeutic targets and inhibit SARS-CoV-2 replication
- Funded by ANR
- Total publications:244 publications
Grant number: Unknown
Grant search
Key facts
Disease
COVID-19Funder
ANRPrincipal Investigator
. Caroline GOUJONResearch Location
FranceLead Research Institution
Institut de Recherche en Infectiologie de Montpellier (IRIM) ? CNRSResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The CRISPR-TARGET-CoV project, coordinated by Caroline Goujou (UMR 9004 Institut de Recherche en Infectiologie de Montpellier (IRIM) - CNRS), aims to produce screens using CRISPR technology at the genome scale in order to identify cofactors and cellular SARS-CoV-2 inhibitors. He will then focus on screening molecules of interest selected for their relevance to the cellular factors identified. The effect of the best molecules will be validated ex vivo in a 3D system of primary respiratory targets of SARS-CoV-2.
Publicationslinked via Europe PMC
Last Updated:9 days ago
View all publications at Europe PMC